Loomis, Sayles & Company’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.48B | Sell |
1,912,310
-22,016
| -1% | -$16.9M | 1.99% | 14 |
|
|
2025
Q4 | $1.49B | Sell |
1,934,326
-45,127
| -2% | -$30.6M | 1.8% | 17 |
|
|
2025
Q3 | $1.11B | Buy |
1,979,453
+38,383
| +2% | +$21.7M | 1.32% | 17 |
|
|
2025
Q2 | $1.02B | Buy |
1,941,070
+305,089
| +19% | +$170M | 1.28% | 17 |
|
|
2025
Q1 | $1.04B | Buy |
1,635,981
+60,632
| +4% | +$41.7M | 1.5% | 17 |
|
|
2024
Q4 | $1.12B | Buy |
1,575,349
+393,997
| +33% | +$331M | 1.42% | 17 |
|
|
2024
Q3 | $1.24B | Sell |
1,181,352
-35,504
| -3% | -$39.5M | 1.63% | 16 |
|
|
2024
Q2 | $1.28B | Buy |
1,216,856
+9,661
| +0.8% | +$9.37M | 1.76% | 16 |
|
|
2024
Q1 | $1.16B | Sell |
1,207,195
-11,872
| -1% | -$11.3M | 1.65% | 16 |
|
|
2023
Q4 | $1.07B | Sell |
1,219,067
-13,812
| -1% | -$11.4M | 1.64% | 16 |
|
|
2023
Q3 | $1.01B | Sell |
1,232,879
-44,605
| -3% | -$35.1M | 1.74% | 16 |
|
|
2023
Q2 | $918M | Sell |
1,277,484
-34,923
| -3% | -$26.9M | 1.48% | 17 |
|
|
2023
Q1 | $1.08B | Sell |
1,312,407
-25,274
| -2% | -$19.1M | 1.87% | 15 |
|
|
2022
Q4 | $965M | Sell |
1,337,681
-378,936
| -22% | -$280M | 1.93% | 17 |
|
|
2022
Q3 | $1.18B | Sell |
1,716,617
-48,171
| -3% | -$30.3M | 2.4% | 15 |
|
|
2022
Q2 | $1.04B | Sell |
1,764,788
-783,259
| -31% | -$509M | 1.94% | 17 |
|
|
2022
Q1 | $1.78B | Sell |
2,548,047
-81,104
| -3% | -$51.3M | 2.38% | 12 |
|
|
2021
Q4 | $1.66B | Sell |
2,629,151
-127,584
| -5% | -$78.4M | 2.01% | 14 |
|
|
2021
Q3 | $1.67B | Buy |
2,756,735
+2,511
| +0.1% | +$1.56M | 2.05% | 15 |
|
|
2021
Q2 | $1.54B | Sell |
2,754,224
-122,144
| -4% | -$61.9M | 1.86% | 18 |
|
|
2021
Q1 | $1.36B | Sell |
2,876,368
-88,215
| -3% | -$42.9M | 1.76% | 20 |
|
|
2020
Q4 | $1.43B | Sell |
2,964,583
-211,415
| -7% | -$114M | 1.89% | 19 |
|
|
2020
Q3 | $1.78B | Sell |
3,175,998
-83,700
| -3% | -$50.8M | 2.59% | 12 |
|
|
2020
Q2 | $2.03B | Sell |
3,259,698
-233,115
| -7% | -$132M | 3.26% | 9 |
|
|
2020
Q1 | $1.71B | Sell |
3,492,813
-199,862
| -5% | -$82.4M | 3.51% | 7 |
|
|
2019
Q4 | $1.39B | Buy |
3,692,675
+100,878
| +3% | +$33.9M | 2.36% | 11 |
|
|
2019
Q3 | $996M | Buy |
3,591,797
+311,476
| +9% | +$92.2M | 1.92% | 19 |
|
|
2019
Q2 | $1.03B | Buy |
3,280,321
+103,634
| +3% | +$34.5M | 1.92% | 18 |
|
|
2019
Q1 | $1.3B | Buy |
3,176,687
+15,540
| +0.5% | +$6.4M | 2.56% | 8 |
|
|
2018
Q4 | $1.18B | Sell |
3,161,147
-185,133
| -6% | -$67.8M | 2.79% | 7 |
|
|
2018
Q3 | $1.35B | Buy |
3,346,280
+41,138
| +1% | +$15.7M | 2.65% | 8 |
|
|
2018
Q2 | $1.14B | Buy |
3,305,142
+485,387
| +17% | +$152M | 2.31% | 11 |
|
|
2018
Q1 | $971M | Buy |
2,819,755
+718,144
| +34% | +$250M | 2.06% | 17 |
|
|
2017
Q4 | $790M | Buy |
2,101,611
+231,560
| +12% | +$93.8M | 1.64% | 21 |
|
|
2017
Q3 | $836M | Buy |
1,870,051
+47,755
| +3% | +$22.7M | 1.82% | 20 |
|
|
2017
Q2 | $895M | Buy |
1,822,296
+98,813
| +6% | +$43.2M | 2.11% | 11 |
|
|
2017
Q1 | $668M | Buy |
1,723,483
+8,178
| +0.5% | +$3.03M | 1.66% | 19 |
|
|
2016
Q4 | $630M | Buy |
1,715,305
+567,188
| +49% | +$216M | 1.55% | 23 |
|
|
2016
Q3 | $462M | Buy |
+1,148,117
| New | +$461M | 1.17% | 29 |
|
|
2014
Q1 | – | Sell |
-8,825
| Closed | -$2.43M | – | 772 |
|
|
2013
Q4 | $2.43M | Buy |
8,825
+1,019
| +13% | +$293K | 0.01% | 594 |
|
|
2013
Q3 | $2.44M | Buy |
7,806
+416
| +6% | +$109K | 0.01% | 575 |
|
|
2013
Q2 | $1.66K | Buy |
+7,390
| New | +$1.72M | 0.01% | 575 |
|
Other funds holding REGN
VCM
N
Loomis, Sayles & Company's REGN Position: Q1 2026 in Review
Loomis, Sayles & Company reduced its Regeneron Pharmaceuticals (REGN) stake by 1.1% in Q1 2026, selling an estimated $16.9M and leaving 1,912,310 shares worth $1.48B. The position accounts for 1.99% of the portfolio, ranked #14.
Loomis, Sayles & Company first reported a position in REGN in Q2 2013 and has held it in 42 quarters since. The position peaked at $2.03B in Q2 2020. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Loomis, Sayles & Company held 1,912,310 shares of Regeneron Pharmaceuticals worth $1.48B as of Q1 2026.
- Loomis, Sayles & Company sold 22,016 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $16.9M.
- Regeneron Pharmaceuticals made up 1.99% of Loomis, Sayles & Company's portfolio in Q1 2026, its #14 holding.
- Loomis, Sayles & Company first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
- Loomis, Sayles & Company's Regeneron Pharmaceuticals position peaked at $2.03B in Q2 2020.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Loomis, Sayles & Company's 13F filing for Q1 2026, filed 14 May 2026.